Loading...
•
Dec 31, 2020
InspireMD Q4 2020 Earnings Report
InspireMD's Q4 2020 results were negatively impacted by a litigation settlement and COVID-19, leading to decreased revenue and gross profit, but the company made progress on strategic initiatives and improved its cash position through public offerings.
Key Takeaways
InspireMD reported a significant decrease in revenue for Q4 2020, primarily due to a litigation settlement and the impact of COVID-19 on procedure volumes. Gross profit also declined significantly. However, the company highlighted progress in strategic initiatives, including IDE approval in the US and expansion in Latin America and China, and improved its cash position through public offerings.
Revenue decreased by 84.4% to $158,000 due to a litigation settlement and COVID-19 impacts.
Gross profit decreased by 250.6% to negative $390,000, primarily due to the settlement.
Operating expenses increased by 20.4% to $3,328,000 due to investments in infrastructure and personnel.
Net loss totaled $3,853,000, or $0.10 per share, compared to a net loss of $2,557,000, or $0.57 per share, for the same period in 2019.
InspireMD
InspireMD
InspireMD Revenue by Segment
Revenue by Segment
CGuard EPS Revenue
CapyFin.com Forward Guidance
The company did not provide specific financial guidance, but expressed optimism for 2021, citing foundational achievements in 2020, including IDE approval, market expansion, and improved financial position.
Positive Outlook
- FDA approval of IDE application for CGuard™ EPS pivotal study in the United States.
- Expansion of market presence with CGuard registration and distribution in Brazil.
- Investment and distribution agreement to enter mainland China.
- Applying for regulatory and reimbursement approvals in new markets such as France, Taiwan and Korea.
- Improved cash position after completing multiple public offerings.
Challenges Ahead
- Revenue was negatively impacted by the settlement of litigation with a former distributor.
- COVID-19 pandemic curtailed the ability to grow revenue.
- Postponement of procedures with CGuard EPS due to hospitals shifting resources to patients affected by COVID-19.
- Decrease in sales volume of MGuard Prime EPS due to the impact of COVID-19.
- Gross margin decreased due to the settlement with a former distributor.